Brokers Offer Predictions for MOLN Q1 Earnings

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Molecular Partners in a report released on Tuesday, January 27th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.41) for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Molecular Partners’ Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.39) EPS and FY2027 earnings at ($1.64) EPS.

A number of other analysts have also issued reports on MOLN. JPMorgan Chase & Co. reduced their target price on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.58.

Molecular Partners Stock Performance

Molecular Partners stock opened at $4.26 on Wednesday. Molecular Partners has a 52 week low of $3.36 and a 52 week high of $5.35. The firm has a market capitalization of $172.02 million, a price-to-earnings ratio of -2.22 and a beta of 1.07. The company has a 50 day moving average price of $4.24 and a 200 day moving average price of $3.94.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.05.

Key Headlines Impacting Molecular Partners

Here are the key news stories impacting Molecular Partners this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy”/”Strong‑Buy” and a $13 price target (≈205% upside vs. current price), giving investors a clear upside thesis that likely boosted the shares. The Fly
• Positive Sentiment: Analyst R. Burns from HC Wainwright flagged an improving EPS trajectory over 2025–2027 (FY2026 and FY2027 estimates are less negative than FY2025), supporting a recovery narrative despite ongoing losses. MarketBeat
• Neutral Sentiment: HC Wainwright published detailed quarter‑by‑quarter EPS forecasts for 2026–2027 (examples: Q1‑2026 $(0.41), Q2‑2026 $(0.43), Q3‑2026 $(0.43), Q4‑2026 $(0.44)), giving investors a multi‑year model to benchmark execution and cash‑burn expectations. MarketBeat
• Negative Sentiment: Despite the bullish rating, HC Wainwright still projects material net losses (FY2025 $(2.10) per share — worse than the consensus $(1.93)), underscoring that valuation depends on pipeline progress and execution rather than near‑term profitability. MarketBeat

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.